Targeting hypoxia at the forefront of anticancer immune responses
Open accessAbstract
Hypoxia influences immune checkpoint receptors and their respective ligands. In support, we recently demonstrated that hypoxia selectively upregulates programmed cell death ligand 1 (PD-L1) on myeloid-derived suppressor cells (MDSCs) via hypoxia inducible factor 1 α (HIF-1α) binding to a hypoxia-response element (HRE) in the PD-L1 proximal promoter. Furthermore, blockade of PD-L1 under hypoxic conditions enhanced MDSC-mediated T-cell activation by attenuating MDSC secretion of IL-6 and IL-10.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
32-134D inhibited the expression of CD47, CD70, IL-6, and IL-10 mRNAs in immune or other stromal cell types, where HIFs play critical roles, rather than in tumor cells.
“which suggests that 32-134D inhibited the expression of these latter mRNAs in immune or other stromal cell types, where HIFs are known to play critical roles (56–61), rather than in tumor cells.”
From HIF inhibitor 32-134D eradicates murine hepatocellular carcinoma in combination with anti-PD1 therapy (2022) · cites this paper as [60]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 10 · Cited by 70
Research works printed but not linked: 6
- Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12:252- 64; PMID:22437870; http://dx.doi.org/10.1038/ nrc3239 · DOI · Paper page
- Noman MZ, Benlalam H, Hasmim M, Chouaib S. Cytotoxic T cells-stroma interactions. Bull Cancer 2011; 98:E19-24; PMID:21339092; http://dx.doi.org/ 10.1684/bdc.2010.1295 · DOI
- Noman MZ, Buart S, Van Pelt J, Richon C, Hasmim M, Leleu N, Suchorska WM, Jalil A, Lecluse Y, El Hage F, et al. The cooperative induction of hypoxia- inducible factor-1 alpha and STAT3 during hypoxia induced an impairment of tumor susceptibility to CTL-mediated cell lysis. J Immunol 2009; 182:3510- 21; PMID:19265129; http://dx.doi.org/10.4049/ jimmunol.0800854 · DOI · Paper page
- Noman MZ, Janji B, Berchem G, Mami-Chouaib F, Chouaib S. Hypoxia-induced autophagy: a new player in cancer immunotherapy? Autophagy 2012; 8:704-6; PMID:22441015; http://dx.doi.org/10.4161/ auto.19572 · DOI
- Hasmim M, Noman MZ, Messai Y, Bordereaux D, Gros G, Baud V, Chouaib S. Cutting edge: Hypoxia-induced Nanog favors the intratumoral infiltration of regulatory T cells and macrophages via direct regulation of TGF- beta1. J Immunol 2013; 191:5802-6; PMID:24227785; http://dx.doi.org/10.4049/jimmunol.1302140 · DOI
- Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol 2012; 12:253-68; PMID:22437938; http://dx.doi.org/10.1038/nri3175 · DOI · Paper page
- Authors
- Noman, M. Z., & Chouaib, S.
- Affiliations
- Inserm (FR)
- Unité INSERM U753; Institut de Cancérologie Gustave Roussy; Villejuif, France
- Venue
- OncoImmunology
- Publisher
- Informa UK Limited
- Published
- 2014-12-02
- Volume
- 3
- Issue
- 12
- Pages
- e954463
- ISSN
- 2162-4011 (ISSN-L)
- 2162-402X
- PMC
- PMC4353170
- OpenAlex
- W2019648143
- Cited by
- 70
- References
- 10
- Citations by year
- 2026: 3 · 2025: 3 · 2024: 2 · 2023: 3 · 2022: 3 · 2021: 15 · 2020: 13 · 2019: 8 · 2018: 8 · 2017: 3 · 2016: 6 · 2015: 3
- FWCI
- 1.93
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- OncoImmunology (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Keywords
- tumor hypoxia, immune checkpoint receptors, PD-L1, myeloid-derived suppressor cells, HIF-1α, hypoxia response element, T cell activation, interleukin-6, IL-10, cancer immunotherapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
